RecruitingNCT04234880

High-resolution Phosphocreatine and Creatine Mapping of Human Muscle and Brain


Sponsor

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Enrollment

50 participants

Start Date

Jan 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

In this study, we aim to develop and validate a noninvasive approach for quantifying and imaging energy metabolism, without contrast agents, on widely available clinical MRI scanners. Briefly, this technique allows specific and selective imaging of the energy metabolite phosphocreatine (PCr), in vivo and non-invasively. PCr is one of the predominant high-energy phosphates present in brain and muscle and one that is altered by common diseases. Although energy metabolism and PCr play a vital role in cellular homeostasis, there currently are no routine diagnostic tests to noninvasively quantify or map the distribution of PCr with clinically acceptable spatial resolution or/and scan time. Here, we demonstrate that the exchangeable guanidinium protons of millimolar concentration PCr can be exploited to detect it via the water signal in MRI with greatly enhanced sensitivity (molar signal) using chemical exchange saturation transfer (CEST) MRI, and its concentration can be quantified using an artificial neural network (ANN). This new technique, dubbed ANNCEST, allowed us to obtain a high-resolution PCr map on human skeletal muscle within 1.5 min, on a 3T clinical MRI scanner equipped with just the standard MRI setup. To put this in a larger perspective, energy metabolism is critical for cell viability and is altered by many common acquired and inherited diseases. ANNCEST is arguably the first to use widely available MRI scanners to noninvasively image tissue energy metabolism of PCr, and thus would have appeal to a broad readership of scientists and clinicians interested in neurology, muscular dystrophies and myopathies as well as cardiology, to name a few.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This observational study develops and validates a new MRI-based technique called ANNCEST that can non-invasively map the energy metabolite phosphocreatine (PCr) in muscles and the brain — without contrast agents or specialized equipment. Since PCr levels reflect how well cells are producing and using energy, this technique could help diagnose or monitor diseases affecting muscles and the nervous system, such as muscular dystrophies, myopathies, and neurological conditions. Healthy adults aged 18 or older with no serious cardiovascular, pulmonary, or musculoskeletal disease, and no MRI contraindications (such as implanted metal devices), may be eligible. Participation involves a single MRI session lasting approximately 1.5 minutes for the novel scan, which is completely non-invasive and does not require any injections. This summary was generated by AI to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

F. M. Kirby Center and Johns Hopkins University Medical School

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04234880


Related Trials